Terapia de inducción acelerada con infliximab en paciente con colitis ulcerosa grave refractaria a corticoides. Caso clínico
Acute severe ulcerative colitis (ASUC) is a potentially life-threatening condition that requires early recognition, hospitalization and adequate treatment. Currently, the use of infliximab in ulcerative colitis (UC) is recommended in the case of severe disease refractory to corticosteroids, once tha...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Lenguaje: | Spanish / Castilian |
| Publicado: |
Sociedad Médica de Santiago
2017
|
| Materias: | |
| Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000801083 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:scielo:S0034-98872017000801083 |
|---|---|
| record_format |
dspace |
| spelling |
oai:scielo:S0034-988720170008010832017-11-27Terapia de inducción acelerada con infliximab en paciente con colitis ulcerosa grave refractaria a corticoides. Caso clínicoFluxá,DanielaFlores,LilianKronberg,UdoMoreno,MauricioFigueroa,CarolinaIbáñez,PatricioLubascher,JaimeSimian,DanielaQuera,Rodrigo Colitis Ulcerative Infliximab time-To-treatment Acute severe ulcerative colitis (ASUC) is a potentially life-threatening condition that requires early recognition, hospitalization and adequate treatment. Currently, the use of infliximab in ulcerative colitis (UC) is recommended in the case of severe disease refractory to corticosteroids, once that superimposed bacterial or viral infections (such as cytomegalovirus or Clostridium difficile) have been excluded. However, conventional weight-based regimens of infliximab might be insufficient for patients with ASUC. Accelerated infliximab induction regimen may increase its serum concentration levels and efficacy by reducing early colectomy rates in these patients. We report a 34 year old female presenting with an ASUC. She was initially treated with hydrocortisone 300 mg/day and mesalazine enemas 4 g/day with an unfavorable clinical response. At the fifth day of therapy, an accelerated induction therapy with infliximab was started in doses of 10 mg/kg at weeks 0, 1 and 4. After the second dose, there was a favorable response with reduction of abdominal pain, stool frequency and hematochezia. She was discharged with prednisone and azathioprine. After a year of starting infliximab, the patient remains in clinical remission.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.145 n.8 20172017-08-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000801083es10.4067/s0034-98872017000801083 |
| institution |
Scielo Chile |
| collection |
Scielo Chile |
| language |
Spanish / Castilian |
| topic |
Colitis Ulcerative Infliximab time-To-treatment |
| spellingShingle |
Colitis Ulcerative Infliximab time-To-treatment Fluxá,Daniela Flores,Lilian Kronberg,Udo Moreno,Mauricio Figueroa,Carolina Ibáñez,Patricio Lubascher,Jaime Simian,Daniela Quera,Rodrigo Terapia de inducción acelerada con infliximab en paciente con colitis ulcerosa grave refractaria a corticoides. Caso clínico |
| description |
Acute severe ulcerative colitis (ASUC) is a potentially life-threatening condition that requires early recognition, hospitalization and adequate treatment. Currently, the use of infliximab in ulcerative colitis (UC) is recommended in the case of severe disease refractory to corticosteroids, once that superimposed bacterial or viral infections (such as cytomegalovirus or Clostridium difficile) have been excluded. However, conventional weight-based regimens of infliximab might be insufficient for patients with ASUC. Accelerated infliximab induction regimen may increase its serum concentration levels and efficacy by reducing early colectomy rates in these patients. We report a 34 year old female presenting with an ASUC. She was initially treated with hydrocortisone 300 mg/day and mesalazine enemas 4 g/day with an unfavorable clinical response. At the fifth day of therapy, an accelerated induction therapy with infliximab was started in doses of 10 mg/kg at weeks 0, 1 and 4. After the second dose, there was a favorable response with reduction of abdominal pain, stool frequency and hematochezia. She was discharged with prednisone and azathioprine. After a year of starting infliximab, the patient remains in clinical remission. |
| author |
Fluxá,Daniela Flores,Lilian Kronberg,Udo Moreno,Mauricio Figueroa,Carolina Ibáñez,Patricio Lubascher,Jaime Simian,Daniela Quera,Rodrigo |
| author_facet |
Fluxá,Daniela Flores,Lilian Kronberg,Udo Moreno,Mauricio Figueroa,Carolina Ibáñez,Patricio Lubascher,Jaime Simian,Daniela Quera,Rodrigo |
| author_sort |
Fluxá,Daniela |
| title |
Terapia de inducción acelerada con infliximab en paciente con colitis ulcerosa grave refractaria a corticoides. Caso clínico |
| title_short |
Terapia de inducción acelerada con infliximab en paciente con colitis ulcerosa grave refractaria a corticoides. Caso clínico |
| title_full |
Terapia de inducción acelerada con infliximab en paciente con colitis ulcerosa grave refractaria a corticoides. Caso clínico |
| title_fullStr |
Terapia de inducción acelerada con infliximab en paciente con colitis ulcerosa grave refractaria a corticoides. Caso clínico |
| title_full_unstemmed |
Terapia de inducción acelerada con infliximab en paciente con colitis ulcerosa grave refractaria a corticoides. Caso clínico |
| title_sort |
terapia de inducción acelerada con infliximab en paciente con colitis ulcerosa grave refractaria a corticoides. caso clínico |
| publisher |
Sociedad Médica de Santiago |
| publishDate |
2017 |
| url |
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000801083 |
| work_keys_str_mv |
AT fluxadaniela terapiadeinduccionaceleradaconinfliximabenpacienteconcolitisulcerosagraverefractariaacorticoidescasoclinico AT floreslilian terapiadeinduccionaceleradaconinfliximabenpacienteconcolitisulcerosagraverefractariaacorticoidescasoclinico AT kronbergudo terapiadeinduccionaceleradaconinfliximabenpacienteconcolitisulcerosagraverefractariaacorticoidescasoclinico AT morenomauricio terapiadeinduccionaceleradaconinfliximabenpacienteconcolitisulcerosagraverefractariaacorticoidescasoclinico AT figueroacarolina terapiadeinduccionaceleradaconinfliximabenpacienteconcolitisulcerosagraverefractariaacorticoidescasoclinico AT ibanezpatricio terapiadeinduccionaceleradaconinfliximabenpacienteconcolitisulcerosagraverefractariaacorticoidescasoclinico AT lubascherjaime terapiadeinduccionaceleradaconinfliximabenpacienteconcolitisulcerosagraverefractariaacorticoidescasoclinico AT simiandaniela terapiadeinduccionaceleradaconinfliximabenpacienteconcolitisulcerosagraverefractariaacorticoidescasoclinico AT querarodrigo terapiadeinduccionaceleradaconinfliximabenpacienteconcolitisulcerosagraverefractariaacorticoidescasoclinico |
| _version_ |
1718436962449227776 |